Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
暂无分享,去创建一个
Robert Gray | Sunil Badve | Edith A Perez | R. Gray | E. Perez | S. Martino | G. Sledge | S. Shak | F. Baehner | S. Badve | J. Sparano | P. Ravdin | L. Shulman | N. Davidson | C. Yoshizawa | L. Goldstein | B. Childs | Steve Rowley | Silvana Martino | George W Sledge | Lawrence N Shulman | Joseph A Sparano | Lori J Goldstein | Barrett H Childs | Carl Yoshizawa | Steve Rowley | Steven Shak | Frederick L Baehner | Peter M Ravdin | Nancy E Davidson
[1] Daniel J Sargent,et al. Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[4] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[6] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[7] The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer , 2005, Nature Clinical Practice Oncology.
[8] E. Winer,et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] J. Sparano,et al. TAILORx: trial assigning individualized options for treatment (Rx). , 2006, Clinical breast cancer.
[10] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[11] Yu Shen,et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. , 2005, Journal of the National Cancer Institute.
[12] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[14] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[15] E. Winer,et al. Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). , 2009 .
[16] Karen A Gelmon,et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Hilsenbeck,et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Donald A. Berry,et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .
[19] J. Bryant,et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Viani,et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials , 2007, BMC Cancer.
[21] Jorma Isola,et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.
[22] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[23] W D Dupont,et al. Histologic grading of breast carcinoma. A reproducibility study , 1994, Cancer.
[24] J. Foekens,et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[26] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[27] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Simon,et al. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. , 2007, Journal of the National Cancer Institute.
[29] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[30] Catherine Legrand. 1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .
[31] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.